In March 2018, the ICA launched the International BPA Registry, a prospective, observational, multicentre, multinational registry to investigate the safety and efficacy of BPA in CTEPH patients who are not eligible for PEA. Enrolment to the registry closed on 31 March 2020 after reaching a total of 502 patients who will be followed up for another 2 years, i.e. until March 2022.
The main objectives for this registry are to:
- Investigate the safety and efficacy of BPA in CTEPH patients
- Assess the change in haemodynamic values from baseline to post BPA
- Compare and contrast BPA techniques across regions and sites
Expert centres from Europe, Japan and the United States taking care of CTEPH patients and performing BPA are participating in this registry. The initialisation of sites has been completed. For a list of participating centres, please visit the registry’s entry on clinicaltrials.gov.
Funding of the International BPA Registry has been secured by the financial support of Bayer AG.
More information is available on clinicaltrials.gov under NCT03245268.